Has Matthew Heeney received payments from drug or device companies?

Yes. Drug and device makers reported $100,977 in general payments to Matthew Heeney across 82 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Heeney did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Heeney come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Heeney

Pediatric Hematology-Oncology · Boston, MANPI 1437118478

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 22.9%. Among pediatric hematology-oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$100,977in general payments, 2019–2025

Across 82 payments — averaging $1231.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$23K
Vertex$22K
Octapharma USA, Inc.$19K
Pfizer$14K
Global Blood Therapeutics, Inc.$7K
Blueprint Medicines Corporation$5K
plus $11K from 3 others

$837,561in research payments, 2019–2025

Across 61 payments — averaging $13,731 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$596K
Pfizer$124K
Agios Pharmaceuticals, Inc.$106K
Novartis Pharma AG$12K

What the payments were for

Consulting fees$49,54249%
Speaking & faculty fees$13,02313%
Travel & lodging$36,00336%
Food & beverage$2,4102%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	37	$23,112
Vertex	6	$22,203
Octapharma USA, Inc.	5	$18,960
Pfizer	13	$13,656
Global Blood Therapeutics, Inc.	8	$7,019
Blueprint Medicines Corporation	1	$5,000
Dova Pharmaceuticals	2	$4,249
Agios Pharmaceuticals, Inc.	7	$3,392
Sanofi	3	$3,387

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OXBRYTA$14,600
ADAKVEO$14,199
DOPTELET$4,200
PYRUKYND$3,290

How this compares

$100,977 in reported general payments places this provider in the 95th percentile of 114 pediatric hematology-oncology providers in Massachusetts.

See all pediatric hematology-oncology providers in Massachusetts →

Other pediatric hematology-oncology in Boston

Leslie KeanBoston$558K
Todd GolubBoston$213K
Rachael GraceBoston$201K
Stacy CroteauBoston$117K
Susan PerrineBoston$96K
Christine DuncanBoston$89K
Eric GrabowskiBoston$56K
Derek HansonBoston$54K
Susan ParsonsBoston$47K
Karen BrideBoston$47K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →